Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972777 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
A Phase 2 study of Bacterial Conjunctivitis, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 474
- Enrollment target
- 1
- Study location
NCT00972777: Completed Phase 2 study of Bacterial Conjunctivitis, sponsored by Bausch & Lomb Incorporated.
NCT00972777 is a Phase 2 study of Bacterial Conjunctivitis that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 474 participants, below the 557-participant average among 7 other Bacterial Conjunctivitis trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00972777, a Phase 2 study of Bacterial Conjunctivitis, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 474 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.
Primary Outcome
The absence of both conjunctival discharge and bulbar conjunctival injection.
Conditions Studied
Interventions
- DRUG Besifloxacin
- DRUG Vehicle (Placebo)
Study Locations (1)
New York
- Bausch & Lomb Incorporated - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
What the finished NCT00972777 record still lists
NCT00972777 is an interventional study that assigns participants to a tested intervention. The registered 474 participants enrollment target is mid-sized for trials with a published cap, below the 557-participant average among 7 other Bacterial Conjunctivitis trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Bacterial Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Besifloxacin is the first listed.
NCT00972777 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00972777 about?
NCT00972777 is a clinical study titled "Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis". This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.
What is the current status of trial NCT00972777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 474 participants. The study started on 2009-10. Estimated completion is 2011-02.
What conditions does trial NCT00972777 study?
This clinical trial studies the following conditions: Bacterial Conjunctivitis.
What interventions are being tested in trial NCT00972777?
The interventions under investigation include: Besifloxacin (DRUG), Vehicle (Placebo) (DRUG).
Who is sponsoring clinical trial NCT00972777?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00972777 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
RECRUITING · Phase 3
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
COMPLETED · Phase 3
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
COMPLETED · Phase 3
-
AL-15469A for the Treatment of Bacterial Conjunctivitis
COMPLETED · Phase 3
-
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
COMPLETED · Phase 4
-
AL-15469A for the Treatment of Bacterial Conjunctivitis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624996 · 474 participants · Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- NCT06051695 · 474 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- NCT06632977 · 474 participants · Phase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia